| abstract |
Use of a Zc3h12b gene or protein thereof and an establishment method for a liver disease animal model. By using a gene editing technology, the Zc3h12b gene of medaka is targeted and knocked out, and the medaka deleting the ZC3H12B protein product is established. All exhibits different degrees of liver diseases such as hepatobiliary hyperplasia and fusion, hepatocyte fatty degeneration, and fibrosis, exhibits significant fatty liver with the increase of months of age, local cyst necrosis, obvious lymphocyte infiltration in hepatic sinusoids, and abnormal increase in the number of macrophages. Furthermore, the cells in which human tumor markers CK19, SMA and GPC3 are positive are also detected, indicating that ZC3H12B can be used as a therapeutic target and biomarker for intrahepatic cystadenoma, intrahepatic cystadenocarcinoma, or fatty liver or liver cancer related thereto. Medaka deleting Zc3h12b can be used as an animal model to study the pathological process of intrahepatic cystadenoma, intrahepatic cystadenocarcinoma or both. |